Articles tagged with Flu Vaccines
A novel vaccine strategy using VLPs could provide a more robust immune response and shorter development time compared to traditional vaccines. Researchers have already made VLP vaccines that show complete protection against H5N1 and 1918 influenza viruses.
World-renowned virologist Professor Albert Osterhaus emphasizes the importance of preparedness in the face of swine-origin flu. He stresses that there is room for improvement in influenza vaccine production and that adequate stockpiles of antibiotics, antivirals, and vaccines are crucial for effective treatment.
A recent study found that infants who receive the pneumococcal conjugate vaccine (PCV) after the DPTaP-Hib vaccine experience less pain than those who receive it first. The authors suggest varying the order of vaccine administration to reduce pain.
Researchers are working on a novel flu vaccine that uses cell culture-based technology to produce immune-boosting signals on the surface of the virus. The goal is to provide better protection against viral pneumonia, especially in elderly populations.
A new delivery method of flu vaccine using microneedle skin patches has shown comparable effectiveness to conventional intramuscular injections. The patch-based approach eliminates pain, increases convenience and could lead to improved seasonal vaccination coverage.
Researchers at Saint Louis University have developed a universal influenza vaccine that evokes high antibody titers, similar to those found in small animals infected with the disease. The vaccine, known as BIPCV, is well-tolerated and safe, even at low doses.
A new study published by the University of Leicester suggests that a six-month time lag may occur before effective vaccines can be manufactured during a pandemic flu outbreak. The study proposes a pre-pandemic vaccination approach to mitigate the worst effects of pandemic flu, which could potentially protect people years in advance.
Rice University scientists developed a computerized method to test flu vaccine efficacy against multiple strains, outperforming existing tests. The new approach may help create more effective vaccines for both seasonal and bird flu, improving global preparedness.
A new vaccine formula has been discovered that boosts T cell immunity to protect humans from bird flu, a highly virulent virus. The formula adds a potent immune modulator to existing flu vaccines, improving their effectiveness and providing potential protection against a pandemic.
Scientists at Emory Vaccine Center develop virus-like particles to combat H5N1 influenza. Mice immunized with VLPs showed long-term protection against lethal infection, offering an alternative to traditional chicken egg-based vaccines.
A recent study has identified a common attachment site on influenza A virus subtypes that can be targeted to develop a universal flu vaccine. This breakthrough discovery was made by researchers at The Scripps Research Institute and provides a blueprint for the development of new antiviral drugs.
The discovery of the CR6261 antibody is good news for researchers aiming to design a universal flu vaccine. The antibody has the potential to treat unvaccinated individuals infected with the flu and provides broad protection against various influenza viruses, including pandemic strains.
Experts urge grocery stores to promote free flu vaccinations instead of free antibiotics during cold and flu season. A recent study shows that workers who received flu vaccine lost fewer days of work due to illness.
Workers aged 50-64 who received the flu vaccine lost fewer days of work and worked less time while ill compared to unvaccinated individuals. The study found a significant reduction in illness-related workdays and improved worker productivity after vaccination.
A new survey of 4,000 American adults reveals that fewer than one-third have been vaccinated against the flu, citing misperceptions and lack of time as main reasons. The CDC's National Influenza Vaccination Week aims to encourage greater use of influenza vaccines through December.
A randomized clinical trial found that half-dose influenza vaccine produced similar antibody responses to full-dose vaccines in healthy adults. Women had a greater response to both doses, suggesting guidelines should consider sex as well as age. This study supports the validity of dose reduction strategies during vaccine shortages.
College students who receive flu vaccines experience significantly fewer flu-like illnesses and impairments in academic performance. Vaccination was associated with a reduction of half-day illnesses, one day of missed class per 17 vaccinated students.
A University of New South Wales researcher calls for a more flexible approach to vaccine funding, considering quality-of-life impacts. This could lead to improved productivity, reduced sick leave for parents, and enhanced herd immunity against diseases such as chickenpox and shingles.
Research suggests that flu vaccination can lower the risk of venous thrombotic embolism (VTE) in people with cardiovascular disease. The protective effect was more pronounced in those under 52 years old. Further studies are needed to confirm this relationship and explore underlying mechanisms.
A recent study published in Pediatrics found that flu vaccination rates for adolescents with asthma and other illnesses are still low, ranging from 8-15% over the study period. However, the researchers suggest that a universal influenza vaccination approach may increase coverage among this population.
Research by the University of Rochester Medical Center found that flu vaccines are effective in protecting children from respiratory viruses, even during years with poor vaccine matches. Vaccination is crucial for preventing illnesses, as it can prevent up to 2,250 hospitalizations and 270,000 to 650,000 doctor visits.
A novel intranasal influenza vaccine has elicited immune responses more than 20 times higher than traditional vaccines, using only half the standard antigen dose. The vaccine's nanoemulsion-based adjuvant system triggers unparalleled mucosal and systemic immunity without pro-inflammatory materials or cytokines.
A new model predicts that vaccinating infants with PCV7 can prevent over 357,000 deaths during an influenza pandemic while saving $7 billion in costs. The research also shows routine pneumococcal vaccination can reduce flu-related deaths and costs in a typical season.
Two studies published in PLOS Medicine show that increasing flu vaccination rates can decrease the burden of influenza. A universal immunization program in Ontario led to reductions in flu-related deaths, hospitalizations, and emergency department visits compared to other provinces.
A CDC-funded study found that vaccinating new mothers and family members against influenza before a newborn leaves the hospital significantly boosts immunization rates. The 'cocooning effect' also protects unprotected children from the flu, which can be life-threatening to infants.
A Phase III study found that the high-dose influenza vaccine increased immune responses to all three influenza strains compared to the standard vaccine in adults 65 years old and older. The new vaccine also showed increased immune response in those with no measurable protective antibodies before vaccination.
A study found that a higher dose of flu vaccine boosts the immune response in people aged 65 and older, increasing antibody levels by 30-80% compared to the standard dose. This could lead to better protection against the flu for those most at risk.
MedImmune presents nine abstracts on respiratory syncytial virus (RSV) and influenza, providing insight into infectious disease prevention. The research focuses on RSV therapy, healthcare costs, and mechanisms of action for the monoclonal antibodies palivizumab and motavizumab.
Researchers have discovered a single vaccine that can protect chickens, cats, and humans against deadly bird flu pandemics. The vaccine uses a 'backbone' from the H9N2 virus to offer universal protection across multiple species.
The Elsevier journal Vaccine released a comprehensive supplement dedicated to influenza vaccines, supported by the International Federation of Pharmaceutical Manufacturers and Associations. Key findings include discussions on pandemic influenza vaccine challenges and the importance of robust global surveillance systems.
A new study has found that a single low-dose booster vaccine can generate an excellent response in people who have been vaccinated up to 7 years ago. This means that proactively immunizing the public with stockpiled pre-pandemic vaccines could be used as a potential vaccination strategy against pandemic influenza.
A hospital-based case-control study found that pneumococcal vaccination was associated with a 50% lower risk of heart attacks two years after vaccination. The study suggested that the pneumonia vaccine may protect against heart attacks by preventing pneumonia, which has been linked to triggering heart attacks.
A recent study published in Archives of Pediatrics & Adolescent Medicine found that the flu vaccine was not associated with reduced hospitalizations or outpatient visits among children under 5. The mismatch between the strains of virus in the vaccine and circulating strains may have contributed to this outcome.
Researchers at Duke University Medical Center found that a maternal diet rich in methyl donors increases the development and severity of asthma in mice. The study also identified specific genes modified by methylation as likely underlying causes of the increased disease severity.
Researchers have found that adding a new component to vaccines for influenza might enable broad protection against avian and seasonal influenza A viruses. Memory T cells from individuals infected with seasonal influenza A cross-react with H5N1, suggesting improved immunity.
A study conducted in Bangladesh found that vaccinating mothers during pregnancy with the flu shot can greatly reduce a newborn's risk of infection, with a 63% reduction in proven influenza illness among infants. The study also showed a 36% decrease in serious respiratory illnesses for both mothers and infants.
Researchers analyzed data from over 700 elderly patients and found no significant reduction in all-cause mortality among those vaccinated against flu. Despite initial reports of a large mortality benefit, the study controlled for various variables and concluded that any potential benefit was small and statistically non-significant.
Scientists at the University of Pittsburgh Center for Vaccine Research are testing vaccines designed to protect against the deadliest strain of avian flu, H5N1. The $3.6M grant will support animal studies using virus-like particles that could potentially offer enhanced protection against new strains.
Researchers at UTMB have tested a new universal vaccine effective against multiple influenza strains, with promising results in a Phase I clinical trial. The vaccine candidate, VaxInnate's M2e, could provide a safe and highly effective solution to prevent seasonal and pandemic influenza A.
Researchers analyzed 1173 cases of community-acquired pneumonia and found that flu vaccination was not associated with a reduced risk. The study suggests that the vaccine may not be effective in reducing influenza infection in elderly individuals at risk of pneumonia.
A Group Health study found that flu vaccination had no protective effect against pneumonia in elderly patients. The largest case-control study of flu vaccine use in the elderly revealed a lack of correlation between vaccination and reduced risk of pneumonia.
A recent study suggests that booster vaccination with a newer strain of H5N1 avian influenza can be more effective than simply vaccinating with the current vaccine. The study shows that priming with an earlier vaccine can enhance immune responses to single-dose vaccination schedules, making it a potential strategy for pandemic control.
Researchers found that men vaccinated in the morning showed strongest immune response to both hepatitis and influenza vaccines. The study's results have implications for vaccination timing, suggesting that adults could be vaccinated at specific times of day to increase their protection against flu.
Researchers at the University of Pennsylvania School of Medicine have developed a potential new way to vaccinate against avian flu by using synthetic DNA vaccines that induce broad immune responses against pandemic flu. This approach could allow for quick mobilization during an epidemic and has implications for non-avian types of flu.
Researchers traced flu samples from around the world to determine migration patterns, finding Asia is the breeding ground for new strains. The study's 'antigenic map' shows relationships between viruses and helps predict future outbreaks.
Researchers have developed a faster way to generate human monoclonal antibodies against influenza virus by tapping the immune system at peak powers. The method was tested on human volunteers and showed promising results, potentially finding broad application towards almost any infectious disease.
Researchers have developed a rapid way to produce human monoclonal antibodies against the flu, overcoming technical barriers that slowed their development. The new technique could potentially be used for diagnosis and treatment of other infectious diseases.
A new vaccine under development has shown promising results in mice, protecting against highly pathogenic bird flu and its variants for a year or longer. The vaccine uses an adenovirus vector technology, which can be produced quickly and stored for long periods, making it an attractive option for pandemic preparedness.
Researchers analyzed 13,000 virus samples from 2002 to 2007 to understand migration patterns of seasonal flu. They found that East and Southeast Asia serves as a source for influenza A (H3N2) viruses globally, with new strains emerging in the region before spreading to other parts of the world.
A study found that flu viruses originating in East and Southeast Asia spread globally, with strains emerging in Asia first, followed by Europe and North America. The research aims to improve flu vaccine design by focusing surveillance efforts on these regions.
Research found that annual flu vaccines reduced acute respiratory illness and exacerbations of COPD by 67% and 50%, respectively. Patients with severe COPD experienced a 75% reduction in respiratory problems.
A new HIV/AIDS vaccine is being tested in a phase 1 clinical trial at Beth Israel Deaconess Medical Center in Boston. The vaccine uses a replication-incompetent adenovirus vector encoding an HIV-1 envelope gene, aiming to overcome the problem of preexisting immunity to common vaccine vectors.
A new study confirms the close link between viral colds and ear infections in young children, identifying adenovirus, respiratory syncytial virus, and coronavirus as primary causes. Researchers recommend avoiding exposure to sick children, day care attendance, and using influenza vaccine to prevent respiratory viral infection.
Researchers from UT Knoxville have made a groundbreaking discovery about memory B cells, which are crucial for fighting off influenza infections. By analyzing where these cells reside after an infection, scientists can develop more effective vaccines that target specific strains and subtypes of the flu virus.
A new study published in Pediatrics found that 23% of children hospitalized with influenza had a previous hospitalization during the most recent flu-vaccine season. This suggests that providing in-hospital vaccinations to those at highest risk may aid in reducing rates of pediatric hospitalization for influenza.
Researchers at the University of Pittsburgh's Center for Vaccine Research have developed a vaccine against the deadliest strain of avian flu, H5N1. The vaccine produced a strong immune response in mice and protected them from death following infection with the virus.
Scientists have discovered a way to eliminate the negative effect of M2 protein on anti-flu vaccination, increasing efficacy while maintaining safety. This breakthrough could lead to more effective and strain-specific vaccines against seasonal flu.
Global health experts Laurie Garrett and David Fidler propose stockpiling highly specific influenza vaccines and antiviral medicines in Hong Kong to overcome the virus sharing impasse. The proposal aims to benefit developing countries by ensuring they have access to vaccine, reducing the risk of pandemic influenza.
A study found significant decreases in illness and death rates for 13 vaccine-preventable diseases in the US, including near 100% declines for some diseases like diphtheria, measles, and smallpox. High vaccine coverage levels have contributed to these achievements.
A study found that antiviral medications significantly reduced the risk of death from flu in hospitalized adults, even when given up to four days after symptom onset. The research supports the use of antivirals for treating hospitalized patients with influenza.